Amphastar Pharmaceuticals, Inc. (AMPH) — 分析摘要
Amphastar Pharmaceuticals, Inc.(AMPH)的市值为879.21百万美元,最近一年的营收同比增长了-1.7%。净利润率为13.6%。当前市盈率为11.1倍。
核心要点
- 营收同比变化-1.7%
- 净利润率13.6%
- 市盈率11.1倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,AMPH的营收增长为-1.7%,市盈率为11.1倍。
Amphastar Pharmaceuticals, Inc. (AMPH)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
Debt/EBITDA 为 4.1x — 杠杆偏高
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
1,976
总部
RANCHO CUCAMONGA, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。